

Relationship of Serum Adiponectin With Blood Lipids, HbA_{1c}, and hs-CRP in Type II Diabetic Postmenopausal Women

Mohammad Taghi Goodarzi,^{1*} Hossein Babaahmadi-Rezaei,¹
Manizheh Kadkhodaei-Eliaderani,² and Shahram Haddadinezhad³

¹Department of Biochemistry and Nutrition, Medical School,
Hamadan University of Medical Sciences, Hamadan, Iran

²Department of Biochemistry, Jundi-Shapour University of Medical Sciences, Ahwaz, Iran

³Department of Internal Medicine, Medical School,
Hamadan University of Medical Sciences, Hamadan, Iran

Adipose tissue has been considered an important endocrine organ. Adiponectin secretes from adipose tissue and plays an important role in the regulation of glycemia, β -oxidation in muscle, and decreased insulin resistance in the liver. The objectives of this study were to compare the levels of adiponectin, hs-C-reactive protein (CRP), HbA_{1c}, and blood lipids among diabetic and healthy postmenopausal women, and to determine the relationship between circulating adiponectin and development of type II diabetes. This case-control study was performed on 28 diabetic and 42 age-matched healthy women. All participants were postmenopausal. Serum adiponectin concentrations, serum triglycerides (TG), cholesterol, low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C)

concentrations were determined. Blood HbA_{1c} and serum hs-CRP were also measured. Adiponectin levels were significantly decreased ($P < 0.01$) in the diabetic patients as compared to normal control subjects. Adiponectin levels were negatively associated with hs-CRP, LDL-C, HbA_{1c}, TG, and total cholesterol (TC). A positive correlation was observed between adiponectin and HDL-C. The obtained data indicate that diabetic women have lower adiponectin levels compared to healthy women. HbA_{1c} as an indicator of glycemic control has a negative correlation with serum adiponectin. Adiponectin may play an important role in the pathogenesis of diabetes, and may be an independent predictor of the development of diabetes in women. *J. Clin. Lab. Anal.* 21:197–200, 2007. © 2007 Wiley-Liss, Inc.

Key words: adiponectin; hs-CRP; glycated hemoglobin

INTRODUCTION

Adipose tissue, in addition to its function as the major storage depot for lipids, plays active roles in normal metabolic homeostasis.

Adiponectin is a hormone produced solely by adipocytes and is a regulator of glucose and energy homeostasis (1). Adiponectin (also known as ACRP₃₀, aPM₁, AdipoQ, and GBP28) is an adipocyte-derived protein present in circulating plasma with range of 5–30 $\mu\text{g}/\text{mL}$ in healthy humans (2). Adiponectin plays an important role in regulating glycemia, lipidemia, endothelial dysfunction, and the proinflammatory mechanism in humans (3). A low plasma adiponectin concentration is associated with a decrease in whole-body insulin sensitivity in humans (4–6), and was shown

to be predictive of future development of diabetes in few studies (7–9). A diabetes susceptibility locus has been mapped to human chromosome 3q27, where the adiponectin gene is located. Thus both genetic and functional data suggest that adiponectin could be involved in the pathogenesis of type II diabetes (9). Adiponectin levels are negatively associated with obesity, hyperlipidemia, and insulin resistance (3). In

*Correspondence to: Dr. M.T. Goodarzi, Department of Biochemistry and Nutrition, Medical School, Hamadan University of Medical Sciences, Post code 65178, Hamadan, Iran.

E-mail: mtgoodarzi@yahoo.com

Received 27 August 2006; Accepted 28 February 2007

DOI 10.1002/jcla.20175

Published online in Wiley InterScience (www.interscience.wiley.com).

addition, adiponectin appeared to have substantial anti-inflammatory properties in in vitro and in vivo animal studies (10). Furthermore, the roles of adiponectin in stimulating β -oxidation in muscle and decreasing insulin resistance in the liver indicate its possible involvement in the development of type II diabetes (11). Previous studies have not fully evaluated the potential association between adiponectin levels and circulating inflammatory marker and lipoprotein abnormalities among diabetic women (3). Jaleel et al. (12) determined serum adiponectin concentrations in diabetic type II postmenopausal women with and without the complications of ischemic heart disease. They showed that blood lipid concentrations increased but HDL decreased with a decrease in adiponectin concentration. However, they indicated that the mechanism by which adiponectin affects HDL is unknown. In this study we examined the correlation of serum adiponectin concentration with HbA1c and blood lipid profiles in diabetic and healthy postmenopausal women. Also, the correlation of hs-CRP as an inflammatory marker with serum adiponectin was investigated.

MATERIALS AND METHODS

Study Groups

The study included 28 diabetic women and 42 age-matched healthy women. To avoid the effect of hormones, such as estrogen, progesterone, and androgens, on the plasma levels of adiponectin, all selected diabetic and healthy subjects were postmenopausal. The study protocol was approved by the ethics committee of the Hamadan University of Medical Sciences. Written informed consent was obtained from each participant.

Diabetes Confirmation

In accordance with the criteria of the National Diabetes Data Group (13), confirmation of diabetes required at least one of following: 1) an elevated plasma glucose concentration (fasting plasma glucose ≥ 140 mg/dL, random plasma glucose ≥ 200 mg/dL) plus at least one classic symptom (excessive thirst, polyuria, weight loss, or hunger); 2) no symptom, but at least two elevated plasma glucose concentrations (by the above criteria) on different occasions; or 3) treatment with hypoglycemic medication (insulin or oral hypoglycemic agent). The participants provided information on their age, weight, height, and menopausal status. We calculated the body mass index (BMI) as the ratio of weight (in kilograms) to the square of height (in meters). Participants with cardiovascular disease (angina pectoris, myocardial infarction, coronary bypass surgery,

coronary angioplasty, or stroke), other systemic diseases, or smoking were excluded.

Laboratory Methods

Venous blood was drawn from all patients and control subjects after overnight fasting. Serum samples were kept at -70°C for subsequent assay. Serum adiponectin was measured by means of a competitive enzyme-linked immunosorbent assay (ELISA) kit obtained from Biovendor Laboratory Medicine Inc. (Brno, Czech Republic). Serum C-reactive protein (CRP) was measured using an hs-CRP ELISA kit (DRG Instrument GmbH, Marburg, Germany) and a microplate reader (Rosys Anthos 2010, Wals, Austria). HbA1c was determined using the chromatographic-ion exchange method (Biosystem kit, Spain). Total cholesterol (TC) was measured using cholesterol esterase/cholesterol oxidase/peroxidase reactions. High-density lipoprotein cholesterol (HDL-C) was determined using the phosphotungstic acid/magnesium chloride precipitation method. A triglyceride (TG) assay was performed using lipase/glycerol kinase/glycerol-phosphate oxidase/peroxidase reactions. All lipid assays were carried out using colorimetric methods (Pars Azmun kits, Iran). Low-density lipoprotein cholesterol (LDL-C) was calculated by means of the Friedewald formula (14) from TC, HDL-C, and TG values. All biomarker assays were carried out on a UV-visible spectrophotometer (Spectronic Genesys 2; Spectronic Instruments, USA).

Statistical Analysis

Data are given as the mean \pm SD. An unpaired Student's *t*-test was used to compare the obtained data between the two groups. $P < 0.05$ was considered significant. Spearman correlation coefficient was used to evaluate the bivariate relationship between serum levels of adiponectin and lipoproteins, CRP, and HbA1c. All statistical analyses were performed using the SPSS 13.0 for Windows statistical package (SPSS, Chicago, IL).

RESULTS

The baseline characteristics are shown in Table 1. Serum adiponectin levels were significantly lower in diabetic women compared to healthy women ($P < 0.01$).

As shown in Table 2, in diabetic women the correlation coefficient revealed that the serum levels of adiponectin were positively and strongly associated with HDL-C ($P < 0.01$) and negatively correlated with TG ($P < 0.01$).

Significant and negative associations were also found between adiponectin and CRP ($P = 0.022$), HbA1c ($P = 0.032$), and LDL-C ($P = 0.005$). There was no


TABLE 1. Baseline characteristics of the healthy and diabetic women

| Parameter | Healthy women (n = 42) | Diabetic women (n = 28) | P value |
|----------------------------|------------------------|-------------------------|---------|
| Adiponectin (microgram/mL) | 10.29 ± 1.93 | 7.29 ± 1.42 | <0.001 |
| CRP (mg/liter) | 3.20 ± 1.60 | 9.65 ± 2.02 | <0.001 |
| HbA _{1c} (%) | 5.00 ± 0.65 | 7.98 ± 0.813 | <0.001 |
| Total cholesterol (mg/dL) | 180 ± 18.0 | 223.2 ± 16 | <0.001 |
| HDL-C (mg/dL) | 50.7 ± 5.7 | 42.82 ± 7.10 | <0.01 |
| LDL-C (mg/dL) | 106.4 ± 21.3 | 136.6 ± 18.0 | <0.01 |
| Triglyceride (mg/dL) | 126.2 ± 24.8 | 218.9 ± 33.1 | <0.001 |
| BMI (kg/m ²) | 26.8 ± 2.1 | 26.5 ± 1.9 | 0.137 |
| Age (years) | 56.14 ± 5.5 | 59.5 ± 5.67 | 0.072 |

TABLE 2. Correlation between adiponectin and blood lipids, HbA_{1c}, and CRP in healthy and diabetic women

| Trait | Correlation coefficient (r) | |
|-------------------|-----------------------------|------------------------|
| | Diabetic women (n = 28) | Healthy women (n = 42) |
| CRP | -0.431* | -0.83 |
| HbA _{1c} | -0.407* | -0.451 |
| Total cholesterol | -0.537* | -0.788 |
| HDL-C | 0.847* | 0.813 |
| LDL-C | -0.516* | -0.817 |
| Triglyceride | -0.872* | -0.722 |
| BMI | -0.792* | -0.650 |
| Age | -0.26 | -0.007 |

*P < 0.05.

**Fig. 1.** Comparison of the distribution of subjects (%) in tertiles of adiponectin in diabetic and healthy women (tertile 1 = 3–6.9; tertile 2 = 7–10.9; tertile 3 = 11–14.9 µg/mL).

significant correlation between adiponectin and age ($P = 0.181$) in diabetic women, whereas the correlation was significant with BMI ($P < 0.01$).

The percentage distribution of the diabetic and healthy women in tertiles of adiponectin is shown in Fig. 1. The tertile values of adiponectin were as

follows: tertile 1 = 3–6.9; tertile 2 = 7–10.9; and tertile 3 = 11–14.9 µg/mL.

A higher percentage of diabetic women were in tertile 1 (53.6%) as compared to healthy women (2.4%).

DISCUSSION

This study shows that the serum adiponectin concentrations were lower in diabetic women as compared to healthy women. Similar reports were published by some investigators (15,16), whereas one study failed to observe this difference between diabetic and control subjects (17).

Daimon et al. (7) found a direct correlation between serum levels of adiponectin and age, whereas our data indicate that age does not influence serum adiponectin. Hotta et al. (18) reported the relationship between adiponectin and insulin resistance in rhesus monkeys. They showed that the plasma level of adiponectin began to decrease in the earlier stage of obesity, when insulin resistance and hyperinsulinemia were progressing (18). An accumulation of evidence from animal and human studies demonstrated that adiponectin plays an important role in the pathophysiology of diabetes and is a risk factor for cardiovascular disease (3). The modulation of insulin sensitivity or insulin resistance by adiponectin has been examined extensively (15,16,19). We found a significant and negative correlation between adiponectin and inflammatory marker and TG; however, Zurawska-Klis and Drzewoski (20) did not find any correlation between these factors. A genetic polymorphism in the adiponectin gene was identified as being associated with obesity and insulin resistance. The mechanism behind the influence of adiponectin on insulin sensitivity in humans is currently unclear (17). Adiponectin treatment reverses insulin resistance in animal models (21).

In summary, we found lower levels of adiponectin in diabetic women as compared to healthy women, and there was no correlation between adiponectin and age. HbA_{1c} as an indicator of glycemic control showed a negative correlation with serum adiponectin. Low

adiponectin concentration may predict the development of diabetes and may have an important role in the pathogenesis of diabetes.

REFERENCES

1. Snehalatha C, Mukesh B, Simon M, Viswanathan V, Haffner SM, Ramachandran A. Plasma adiponectin is an independent predictor of type 2 diabetes in Asian Indians. *Diabetes Care* 2003;26:3226–3229.
2. Kondo H, Shimomura I, Matsukawa Y, et al. Association of adiponectin mutation with type 2 diabetes. *Diabetes* 2002;51:2325–2328.
3. Mantzoros C, Li T, Manson J, Meigs J, Hu F. Circulating adiponectin levels are associated with better glycemic control, more favorable lipid profile and reduced inflammation in women with type 2 diabetes. *J Clin Endocrinol Metab* 2005;372:1–22.
4. Tschrirter O, Fritsche A, Thamer C, et al. Plasma adiponectin concentration predict insulin sensitivity of both glucose and lipid metabolism. *Diabetes* 2003;52:239–243.
5. Zoccali C, Mallamaci F, Tripepi G, et al. Adiponectin metabolic risk factors, and cardiovascular events among patient with end-stage renal disease. *J Am Soc Nephrol* 2002;13:134–141.
6. Kazumi T, Kawaguchi A, Sakai K, Hirano T, Yoshino G. Young men with high-normal blood pressure have lower serum adiponectin, smaller LDL size, and higher elevated heart rate than those with optimal blood pressure. *Diabetes Care* 2002;25:971–976.
7. Daimon M, Oizumi T, Saitoh T, et al. Decreased serum levels of adiponectin are a risk factor for the progression to type II diabetes in Japanese population: the Funagata study. *Diabetes* 2003;26:2015–2020.
8. Lindsay RS, Funahashi T, Hanson RL, et al. Adiponectin and development of type 2 diabetes in Pima Indian population. *Lancet* 2002;360:57–58.
9. Spranger J, Kroke A, Mohlig M, et al. Adiponectin and protection against type 2 diabetes mellitus. *Lancet* 2003;361:226–228.
10. Chandran M, Phillips SA, Ciaraldi T, Henry RR. Adiponectin more than just another fat cell hormone? *Diabetes Care* 2003;26:2442–2450.
11. Berg AH, Combs TP, Scherer PE. ACR30/adiponectin: an adipokine regulating glucose and lipids metabolism. *Trends Endocrinol Metab* 2002;13:84–89.
12. Jaleel F, Jaleel A, Aftab J, Rahman MA. Relationship between adiponectin and blood lipids in diabetic type 2 postmenopausal women with and without complication of ischemic heart disease. *Clin Chim Acta* 2006;370:76–81.
13. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other category of glucose intolerance. *Diabetes* 1979;28:1039–1057.
14. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. *Clin Chem* 1972;18:499–502.
15. Weyer C, Funahashi T, Tanaka S, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. *J Clin Endocrinol Metab* 2001;86:1930–1935.
16. Matsubara M, Maruoka S, Katayose. Decreased plasma adiponectin concentration in women with dyslipidemia. *J Clin Endocrinol Metab* 2002;87:2764–2769.
17. Ryan AS, Berman DM, Nicklas BJ, Katayose S. Plasma adiponectin and leptin levels, body composition, and glucose utilization in adult women with wide ranges of age and obesity. *Diabetes Care* 2003;26:2383–2388.
18. Hotta K, Funahashi T, Bodkin NL, et al. Circulating concentration of adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkey. *Diabetes* 2001;50:1126–1133.
19. Stefan N, Vozarova B, Funahashi T, et al. Plasma adiponectin concentration is associated with skeletal muscle insulin receptor tyrosin phosphorylation, and low plasma concentration precedes a decrease in whole-body insulin sensitivity in human. *Diabetes* 2002;51:1884–1888.
20. Zurawska-Klis M, Drzewoski J. Inflammatory markers and adiponectin plasma level in patients with type 2 diabetes. *Pol Arch Med Wewn* 2005;114:652–657.
21. Yamauchi T, Kamon J, Waki H, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipotrophy and obesity. *Nat Med* 2001;7:941–946.